## INTRODUCTION TO THE Q-PLEX<sup>™</sup> HUMAN PNEUMOCOCCAL IgG ASSAYS






# TABLE OF

Q-Plex™ Human Pneumococcal IgG Assays for Vaccine Efficacy	1
Key Benefit of Q-Plex™ Human Pneumococcal IgG Assays	2
Using the Kit with the Q-View™ Imager and Software	3
Why Choose Multiplex ELISAs	4
Reach Out	5
Additional Resources	6

#### Q-PLEX™ HUMAN PNEUMOCOCCAL IgG ASSAYS FOR VACCINE EFFICACY

The Q-Plex<sup>™</sup> Human Pneumococcal IgG (14-Plex) and the Q-Plex<sup>™</sup> Human Pneumococcal IgG (9-Plex) are advanced multiplex assays that can simultaneously detects 23 polyclonal IgG antibodies each one specific to various serotypes of *Streptococcus pneumoniae*.

Pneumococcal infections, which can lead to pneumonia, meningitis, and sepsis, are a serious health threats worldwide, especially for vulnerable groups. These advanced assays allow for the detailed profiling of immune responses against the pneumococcal bacteria, making it an important tool for researchers studying vaccine efficacy, disease epidemiology, and immune system responses.





#### KEY BENEFITS OF Q-PLEX™ HUMAN PNEUMOCOCCAL IgG

• **Comprehensive Analysis:** Measures antibodies against multiple different serotypes of S. pneumoniae in a single well, saving time and reducing the amount of sample needed.

• **High Sensitivity & Specificity:** Provides accurate and reliable data for studying immune responses to pneumococcal infections.

• Accelerates Vaccine Development: A valuable tool in evaluating the immune responses to pneumococcal vaccines, helping researchers identify immune correlates of protection.

• Multiplex Efficiency: Offers the efficiency of multiplex testing without losing sensitivity, making it ideal for large-scale studies and clinical trials.

• Assess Vaccine Effectiveness in Patients: By measuring a broad range of serotype-specific antibodies, the Q-Plex<sup>™</sup> Human Pneumococcal IgG Assays helps clinicians determine if a patient has developed a sufficient immune response to a pneumococcal vaccine, supporting vaccine effectiveness on a patient-by-patient basis.


### USING THE KIT WITH THE Q-VIEW™ IMAGER AND SOFTWARE

In addition to our leading pneumococcal assays, Quansys Biosciences offers a wide range of advanced technologies that enhance research capabilities:

• Multiplex and Singleplex ELISAs: High-performance assays for protein quantification across various fields of research.

• Q-View<sup>™</sup> Imaging Equipment: A high-quality, cost-effective chemiluminescent imager designed for 96-well to 384-well plates. Featuring fast 5-minute read times, a small benchtop footprint, minimal maintenance, and CMOS sensor-based data acquisition.

• Q-View<sup>™</sup> Data Analysis Software: Intuitive and user-friendly software that streamlines data interpretation and analysis, making it easier to analyze results and generate insights.





#### WHY CHOOSE MULTIPLEX ELISAS

Multiplex ELISA technology is a major improvement over traditional assays, allowing the measurement of multiple analytes in a single well. Our Q-Plex<sup>™</sup> Arrays use a unique printing technique to capture distinct antibodies in defined spots on a multi-well plate. This allows researchers to test up to 18 analytes at once, increasing throughput, saving time, and enhancing data quality.

The <u>Q-Plex<sup>™</sup> Human Pneumococcal IgG (14-Plex)</u> and (<u>9-Plex</u>) takes multiplexing to the next level in studying pneumococcal diseases and vaccine responses. By offering high sensitivity and the ability to detect multiple serotypes simultaneously, making it an essential tool for both clinical and preclinical research.



#### **REACH OUT**

For questions and inquiries about Quansys Biosciences products or services, please contact us by phone or through email.

For more information on the <u>Q-Plex<sup>™</sup> Human Pneumococcal IgG (14-</u><u>Plex</u>) kit or the <u>Q-Plex<sup>™</sup> Human Pneumococcal IgG (9-Plex</u>) kit, check out the website by clicking the link below.



#### RECENT PUBLICATIONS



Evaluating patient immunocompetence through antibody response to pneumococcal polysaccharide vaccine using a newly developed 23 serotype multiplexed assay

This recent study, published in Clinical Immunology (2024), introduces a more efficient and accurate method for assessing the immune response to pneumococcal vaccines.

The study highlights a breakthrough with the <u>Quansys Biosciences</u> <u>pneumococcal 23 serotype multiplexed assay</u> that provides a comprehensive approach to testing, overcoming the limitations of traditional methods.

Download the full study here.

#### **OUANSYS** BIOSCIENCES







<u>info@quansysbio.com</u>



www.quansysbio.com